Neurological Disorder Diagnostics Market by Technology (Imaging, and In Vitro Diagnostics), by Disease Indication (Genetic Neurological Disorders, Immunological Neurological Disorders, Paraneoplastic Syndrome, Paraproteinemic Neuropathies, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026

  • Published On : Jun 2018 |
  • Pages : 231 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Neurological Disorder Diagnostics Market- Insights

Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic tools. For instance, according to a study published in Parkinson Association of the Carolinas, 2013, each year, around 10 million people worldwide are suffering from Parkinson disease. Moreover, this accounts for around 60,000 cases in the U.S. alone. According to data published by Alzheimer’s Association in 2017, around 5.5 million people in the U.S. of all ages are suffering from Alzheimer’s dementia

Frequent launches and approvals of novel neurological disorder diagnostics products is expected to drive growth of the market

In the recent past, key players in the market had received approvals and had launched a number of novel technological advanced neurological disorder diagnosis devices in the market, and this is expected to aid in neurological disorder diagnostics market growth. For instance, in April 2018, Canon Medical Systems Corporation launched 1.5T MRI System, Vantage Orian. In April 2018, Siemens Healthineers received U.S. FDA approval for its new SOMATOM go.All and SOMATOM go.Top computed tomography (CT) systems. SOMATOM go.All has 64-slice and provides 0.33-second rotation time, stellar detector technology, and a robust 75 kW generator. SOMATOM go.Top has 128-slice and provides fast scanning. Furthermore, in 2017, Neusoft Medical Systems received U.S. FDA approval for NeuViz Prime CT Scanner.

The global neurological disorder diagnostics market was valued at US$ 10,774.6 Mn in 2017, and is expected to witness a CAGR of 7.3% over the forecast period (2018 – 2026).

Figure 1. Global Neurological Disorder Diagnostics Market Share (%), By Region, 2017

neurological disorder diagnostics market

Source: Coherent Market Insights Analysis (2017)

Increasing strategic collaborations for development of new diagnostic tools is expected to propel the market growth

Strategic collaboration among key players in the market is also expected to be another factor fueling growth of the global neurological disorder diagnosis market growth. For instance, in March 2018, Canon Medical Systems, Kumamoto University, and University of Bordeaux entered into collaborative research for development of deep learning technology in magnetic resonance imaging. In 2017, York Instruments Ltd. signed an agreement for three Magnetoencephalography Systems with three leading universities. The University of York, the University of Glasgow in the U.K., and Germany’s University of Konstanz partnered with York Instruments to develop this technology.

Furthermore, North America neurological disorder diagnostics market, and Asia Pacific neurological disorder diagnostics market are expected to show a good growth in the near future due to increasing adoption of diagnostic devices by hospitals and ambulatory care centers in regions. For instance, according to the data published by the Organisation for Economic Co-operation and Development (OECD), in the U.S., the total unit of Magnetic Resonance Imaging (MRI) in hospital and ambulatory care centers in 2015, were around 39.0 per 1,000,000 inhabitants increasing from 31.5 per 1,000,000 population in 2010. In Asia Pacific, Japan is the only country to have over 100 CT scanners per 1,000,000 population. According to Organisation for Economic Co-operation and Development (OECD), Japan had 107.2 CT scanners per 1,000,000 population in 2014.

High cost of diagnostic tools such as MRI machines and CT scan is a major factor, which is expected to hinder growth of global neurological disorder diagnostics market. Devices of such high cost are not affordable by small hospital facilities in emerging economies such as India, Africa, and China. Therefore, this factor is expected to negatively affect growth of the market. For instance, price of a magnetic resonance imaging (MRI) devices starts from US$ 150,000, and high end device costs over US$ 1 million. Such high cost devices are only affordable by big hospitals and diagnostic laboratories.

Key players operating in the neurological disorder diagnostics market include Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation

Neurological disorder diagnostic tools are those used in diagnosis of various neurological disorders. Neurological disorders can be diagnosed with the use of imaging and in vitro diagnostics techniques. Imaging techniques such as Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are used to create detailed images of organs, bones, soft tissue, blood vessels and different parts of body, while vitro diagnostic techniques consists of techniques such as biopsy, biomarker, blood test, urine test, and genetic testing.

Market Dynamics

Product launches and approvals of novel neurological diagnostic products is expected to be a major driver for growth of the global neurological disorder diagnostics. For instance, in 2016, Koninklijke Philips N.V. launched its latest Philips IQon Spectral CT in Canada. The latest Philips IQon Spectral CT is the world’s first and only spectral detector CT, designed specifically for spectral imaging. With a new dual-layer spectral detector, the IQon Spectral CT has added spectral resolution to conventional CT scanning. Increasing research and development activities for development of novel diagnosis techniques for neurological disorder is also expected to fuel the market growth. For instance, in 2017, researchers from Assistance Publique – Hôpitaux de Paris (AP-HP) in collaboration with ICM researchers (Inserm/CNRS/UPMC) and Metafora Biosystems, developed a diagnostic blood test for De Vivo disease, a rare neurological illness. Increasing prevalence of neurological disorders is also expected to increase demand for diagnostic devices in the near future. For instance, According to World Alzheimer Report 2016, around 47 million people are living with dementia worldwide, and this is expected to increase about three-fold to reach 131 million by 2050. Alzheimer is one of the leading causes of dementia and accounts for an estimated 60% to 80% of all of dementia cases, according to 2018 Alzheimer’s Facts and Figures published by Alzheimer’s Association.

Key features of the study:

  • This report provides in-depth analysis of neurological disorder diagnostics and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global neurological disorder diagnostics based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global neurological disorder diagnostics report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the neurological disorder diagnostics

Detailed Segmentation:

  • Global Neurological disorder diagnostics, By Technology :
    • Imaging
      • Computed Tomography (CT)
      • Magnetic Resonance Imaging (MRI)
      • Nuclear Medicine Imaging
      • Positron Emission Tomography (PET)
      • Single-Photon Emission Computed Tomography (SPECT)
      • Near Infrared Spectroscopic Imaging (NIRS)
      • Electroencephalography (EEG)
      • Magnetoencephalography (MEG)
      • In Vitro Diagnostics
      • Biomarker
      • Biopsy
      • Others
  • Global Neurological disorder diagnostics, By Disease Indication:
    • Genetic Neurological Disorders
      • Alzheimer’s Disease (AD)
      • Parkinson’s Disease (PD)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Huntington's Disease (HD)
      • Others
    • Immunological Neurological Disorders
      • Multiple Sclerosis
      • Others
    • Paraneoplastic Syndrome
    • Paraproteinemic neuropathies
    • Others
  • Global Neurological disorder diagnostics, By End User:
    • Hospitals & Clinics
    • Diagnostic Centers
    • Ambulatory Care Centers
  • Global Neurological disorder diagnostics, By Geography:
    • North America
      • Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-Photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic neuropathies
        • Others
      • By End User
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • U.S.
        • Canada
    • Europe
      •  
      • Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-Photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic neuropathies
        • Others
      • By End User
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia PacificTechnology:
      • Imaging
        • Computed Tomography (CT)
        • Magnetic Resonance Imaging (MRI)
        • Nuclear Medicine Imaging
        • Positron Emission Tomography (PET)
        • Single-Photon Emission Computed Tomography (SPECT)
        • Near Infrared Spectroscopic Imaging (NIRS)
        • Electroencephalography (EEG)
        • Magnetoencephalography (MEG)
      • In Vitro Diagnostics
        • Biomarker
        • Biopsy
        • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic neuropathies
        • Others
      • By End User
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-Photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic neuropathies
        • Others
      • By End User
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-Photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic neuropathies
        • Others
      • By End User
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-Photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic neuropathies
        • Others
      • By End User
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Siemens Healthineers*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Koninklijke Philips N.V.
    • General Electric Company
    • Esaote SpA
    • NeuroLogica Corporation
    • Masimo Corporation
    • York Instruments Ltd.
    • Neusoft Medical Systems
    • Canon Medical Systems Corporation

*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Technology
      • Market Snippet, By Disease Indication
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • PEST Analysis
    • Porter’s Five Forces Analysis
  4. Global Neurological Disorder Diagnostics Market, By Technology, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Imaging
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
      • Segment Trends
        • Computed Tomography (CT)
        • Magnetic Resonance Imaging (MRI)
        • Nuclear Medicine Imaging
        • Positron Emission Tomography (PET)
        • Single-Photon Emission Computed Tomography (SPECT)
        • Near Infrared Spectroscopic Imaging (NIRS)
        • Electroencephalography (EEG)
        • Magnetoencephalography (MEG)
      • In Vitro Diagnostics
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
          • Biomarker
          • Biopsy
          • Others
  5. Global Neurological Disorder Diagnostics Market, By Disease Indication, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Genetic Neurological Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
      • Segment Trends
        • Alzheimer’s Disease (AD)
        • Parkinson’s Disease (PD)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Huntington's Disease (HD)
        • Others
      • Immunological Neurological Disorders
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
        • Segment Trends
          • Multiple Sclerosis
          • Others
      • Paraneoplastic Syndrome
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
      • Paraproteinemic neuropathies
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
        • Segment Trends
      • Others
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Neurological Disorder Diagnostics Market, By End User, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospitals & Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Diagnostic Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Ambulatory Care Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  7. Global Neurological Disorder Diagnostics Market, By Region, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Technology, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Siemens Healthineers
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Koninklijke Philips N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • General Electric Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Esaote SpA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • NeuroLogica Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Masimo Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • York Instruments Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Neusoft Medical Systems
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Canon Medical Systems Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 40 market data tables and 42 figures on “Neurological Disorder Diagnostics Market - Global forecast to 2026”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.